Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript

Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 13, 2026

Artivion Reports Fourth Quarter and Full Year 2025 Financial Results

Fourth Quarter Highlights: GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $388.5 million for the full year of 2024.

PRNewsWire • Feb 12, 2026

Artivion (AORT) Q4 Earnings Surpass Estimates

Artivion (AORT) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago.

Zacks Investment Research • Feb 12, 2026

Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting

1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Benefit of AMDS ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62nd Annual Meeting of the Society of Thoracic Surgeons in New Orleans, Louisiana.   The NEXUS TRIOMPHE IDE trial presentation of 94 patients highlighted 94% patient survival from lesion related death and 91% freedom from disabling stroke at 1-year post-treatment in this high-risk patient group.

PRNewsWire • Feb 2, 2026

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results

ATLANTA, Jan. 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter 2025 financial results will be released on Thursday, February 12, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

PRNewsWire • Jan 29, 2026

Artivion Continues Building Toward Bigger And Better Things

Artivion continues to outperform the med-tech sector, driven by strong execution in stent grafts and On-X valve businesses. Recent clinical updates for the AMDS prosthesis reinforce its safety and efficacy, supporting further adoption and de-risking full commercialization. I expect double-digit long-term revenue growth, expanding EBITDA margins, and a fair value in the high-$50s, justifying a bullish stance.

Seeking Alpha • Dec 29, 2025

Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?

Here is how Artivion (AORT) and Pacific Biosciences of California (PACB) have performed compared to their sector so far this year.

Zacks Investment Research • Nov 26, 2025

Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update

Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion, Inc. (AORT) were among the top contributors to performance. SPS Commerce, Inc. (SPSC), Palomar Holdings, Inc. (PLMR), and Vertex, Inc. (VRTX) were among the top detractors from performance.

Seeking Alpha • Nov 12, 2025

Artivion, Inc. (AORT) Q3 2025 Earnings Call Transcript

Artivion, Inc. ( AORT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Pat MacKin Lance Berry - EVP, COO, CFO & Treasurer Conference Call Participants Lynn Lewis - Gilmartin Group LLC John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to the Artivion Third Quarter 2025 Earnings Call. [Operator Instructions].

Seeking Alpha • Nov 7, 2025

Artivion Reports Third Quarter 2025 Financial Results

Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025 Adjusted EBITDA increased 39% to $24.6 million in the third quarter of 2025 compared to $17.7 million in the third quarter of 2024 Enrolled first patient in ARTIZEN U.S. Investigational Device Exemption trial for Arcevo ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2025. "Our third quarter performance was exceptionally strong as we made progress across each of our strategic initiatives while delivering 16% constant currency revenue growth.

PRNewsWire • Nov 6, 2025